Antiangiogenic therapy for refractory colorectal cancer: Current options and future strategies

Therapeutic Advances in Medical Oncology

Volumn 9, Issue 2, 2017, Pages 106-126

  Riechelmann, Rachel ^a   Grothey, Axel ^b  

^a Instituto do Cancer do Estado de Sao Paulo   (Brazil)

^b MAYO CLINIC   (United States)

Author keywords

antiangiogenic; biomarker; colorectal cancer; monoclonal antibody; tyrosine kinase inhibitor

Indexed keywords

AFATINIB; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; BRIVANIB; CAPECITABINE; CEDIRANIB; CETUXIMAB; DOCETAXEL; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; LINIFANIB; MITOMYCIN; NINTEDANIB; OXALIPLATIN; PANITUMUMAB; PLACEBO; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TIVOZANIB; UNINDEXED DRUG; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE;

EID: 85011604935     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834016676703     Document Type: Review

References (137)

1. Albert D., Tapang P., Magoc T., Pease L., Reuter D., Wei R., et al. (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5: 995-1006.
2. American Cancer Society. (2015) Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society.
3. Bayer HealthCare Pharmaceuticals. (2015) Nexavar (sorafenib) tablets, oral (package insert).
4. Bayer Inc. (2015) Stivarga (regorafenib) tablets, oral (package insert).
5. Bendell J., Powderly J., Lieu C., Eckhardt S., Hurwitz H., Hochster H., et al. (2015) Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 33: Abstract 704.
6. Bendell J., Tournigand C., Swieboda-Sadlej A., Barone C., Wainberg Z., Kim J., et al. (2013) Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Clin Colorectal Cancer 12: 239-247.
7. Bennouna J., Sastre J., Arnold D., Osterlund P., Greil R., Van Cutsem E., et al. (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase III trial. Lancet Oncol 14: 29-37.
8. Bhide R., Cai Z., Zhang Y., Qian L., Wei D., Barbosa S., et al. (2006) Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49: 2143-2146.
9. Boehringer Ingelheim Pharmaceuticals. (2014) OFEV® (Nintedanib) capsules for oral use (package insert).
10. Bouche O., Maindrault-Goebel F., Ducreux M., Lledo G., Andre T., Stopfer P., et al. (2011) Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res 31: 2271-2281.
11. Bruhn M., Townsend A., Khoon L., Shivasami A., Price T., Wrin J., et al. (2014) Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. Int J Cancer 135: 731-741.
12. Buyse M., Burzykowski T., Carroll K., Michiels S., Sargent D., Miller L., et al. (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25: 5218-5224.
13. Cao Y., Tan A., Gao F., Liu L., Liao C., Mo Z., (2009) A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 24: 677-685.
14. Capdevila J., Carrato A., Tabernero J., Grande E., (2014) What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? Crit Rev Oncol Hematol 92: 83-106.
15. Carrato A., Swieboda-Sadlej A., Staszewska-Skurczynska M., Lim R., Roman L., Shparyk Y., et al. (2013) Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 31: 1341-1347.
16. Cascinu S., Graziano F., Catalano V., Staccioli M., Rossi M., Baldelli A., et al. (2002) An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Br J Cancer 86: 744-749.
17. Cassidy J., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. (2011) XELOX versus FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 105: 58-64.
18. Chen C., Sun P., Ye S., Weng H., Dai Q., (2014) Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: a meta-analysis. J BUON 19: 917-924.
19. Choueiri T., (2008) Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 9: 658-671.
20. Chun Y., Vauthey J., Boonsirikamchai P., Maru D., Kopetz S., Palavecino M., et al. (2009) Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. J Am Med Assoc 302: 2338-2344.
21. Colucci G., Gebbia V., Paoletti G., Giuliani F., Caruso M., Gebbia N., et al. (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875.
22. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., et al. (2009) PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15: 21-34.
23. Cunningham D., Atkin W., Lenz H., Lynch H., Minsky B., Nordlinger B., et al. (2010) Colorectal cancer. Lancet 375: 1030-1047.
24. Cunningham D., Lang I., Marcuello E., Lorusso V., Ocvirk J., Shin D., et al. (2013a) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase III trial. Lancet Oncol 14: 1077-1085.
25. Cunningham D., Wong R., D'Haens G., Douillard J., Robertson J., Stone A., et al. (2013b) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. Br J Cancer 108: 493-502.
26. Davies M., Jonas S., Kaur S., Allen-Mersh T., (2000) Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume. Br J Cancer 82: 1004-1008.
27. De Geus-Oei L., Vriens D., van Laarhoven H., van der Graaf W., Oyen W,. (2009) Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50: 43S-54S.
28. De Haas S., Delmar P., Bansal A., Moisse M., Miles D., Leighl N., et al. (2014) Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis 17: 909-920.
29. Del Prete M., Giampieri R., Loupakis F., Prochilo T., Salvatore L., Faloppi L., et al. (2015) Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget 6: 33982-33992.
30. Del Prete M., Scartozzi M., Prochilo T., et al. (2014) LDH serum levels as a predictive factor for global outcome in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. J Clin Oncol 32: Abstract 497.
31. Diaz-Rubio E., Gomez-Espana A., Massuti B., Sastre J., Abad A., Valladares M., et al. (2012) First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 17: 15-25.
32. Douillard J., Cunningham D., Roth A., Navarro M., James R., Karasek P., et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047.
33. Douillard J., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705.
34. Eli Lilly and Company. (2015) Cyramza (ramucirumab) injection for intravenous use (package insert).
35. ® capsules: summary of product characteristics.
36. ® capsules: summary of product characteristics.
37. Fuchs C., Marshall J., Barrueco J., (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26: 689-690.
38. Fuchs C., Marshall J., Mitchell E., Wierzbicki R., Ganju V., Jeffery M., et al. (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786.
39. Gaur S., Chen L., Ann V., Lin W., Wang Y., Chang V., et al. (2014) Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status. Mol Cancer 13: 21.
40. Genentech Inc. (2014) AVASTIN (bevacizumab) solution for intravenous infusion (package insert).
41. Giantonio B., Catalano P., Meropol N., O'Dwyer P., Mitchell E., Alberts S., et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544.
42. Gill S., Berry S., Biagi J., Butts C., Buyse M., Chen E., et al. (2011) Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Curr Oncol 18: S5-S10.
43. Goldberg R., Sargent D., Morton R., Fuchs C., Ramanathan R., Williamson S., et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30.
44. Grothey A., Van Cutsem E., Sobrero A., Siena S., Falcone A., Ychou M., et al. (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase III trial. Lancet 381: 303-312.
45. Guinney J., Dienstmann R., Wang X., de Reyniès A., Schlicker A., Soneson C., et al. (2015) The consensus molecular subtypes of colorectal cancer. Nat Med 21: 1350-1356.
46. Hansen T., Carlsen A., Heegaard N., Sorensen F., Jakobsen A., (2015) Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer 112: 624-629.
47. Hansen T., Christensen R., Andersen R., Garm Spindler K., Johnsson A., Jakobsen A., (2012) The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis 27: 715-720.
48. Hansen T., Christensen R., Andersen R., Sorensen F., Johnsson A., Jakobsen A., (2013) MicroRNA-126 and epidermal growth factor-like domain 7 ' an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer 109: 1243-1251.
49. Hansen T., Nielsen B., Sorensen F., Johnsson A., Jakobsen A., (2014) Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer. Mol Cancer Ther 13: 2238-2245.
50. Hayashi H., Arao T., Matsumoto K., Kimura H., Togashi Y., Hirashima Y., et al. (2014) Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. Oncotarget 5: 2588-2595.
51. Hecht J., Trarbach T., Hainsworth J., Major P., Jager E., Wolff R., et al. (2011) Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29: 1997-2003.
52. Hegde P., Jubb A., Chen D., Li N., Meng Y., Bernaards C., et al. (2013) Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19: 929-937.
53. Hegewisch-Becker S., Graeven U., Lerchenmuller C., Killing B., Depenbusch R., Steffens C., et al. (2015) Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase III trial. Lancet Oncol 16: 1355-1369.
54. Hendlisz A., Deleporte A., Delaunoit T., Marechal R., Peeters M., Holbrechts S., et al. (2015) The prognostic significance of metabolic response heterogeneity in metastatic colorectal cancer. PLoS One 10: e0138341.
55. Hilberg F., Roth G., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., et al. (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774-4782.
56. Hochster H., Hart L., Ramanathan R., Childs B., Hainsworth J., Cohn A., et al. (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26: 3523-3529.
57. Hoff P., Hochhaus A., Pestalozzi B., Tebbutt N., Li J., Kim T., et al. (2012) Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 30: 3596-3603.
58. Hu-Lowe D., Zou H., Grazzini M., Hallin M., Wickman G., Amundson K., et al. (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14: 7272-7283.
59. ® Registry-Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol) 26: 323-332.
60. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
61. Hurwitz H., Tebbutt N., Kabbinavar F., Giantonio B., Guan Z., Mitchell L., et al. (2013) Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 18: 1004-1012.
62. Ince W., Jubb A., Holden S., Holmgren E., Tobin P., Sridhar M., et al. (2005) Association of K-ras, B-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97: 981-989.
63. Infante J., Reid T., Cohn A., Edenfield W., Cescon T., Hamm J., et al. (2013) Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase II study. Cancer 119: 2555-2563.
64. Innocenti F., Owzar K., Jiang C., Sibley A., Niedzwiecki D., Lenz H., et al. (2015) A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated wth chemotherapy and biologics in CALGB 80405. J Clin Oncol 33: Abstract 3599.
65. Jackson A., O'Connor J., Parker G., Jayson G., (2007) Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 13: 3449-3459.
66. Jain R., (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
67. Jain R., (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
68. Joseph M., Bares K., Blachly R., Kuzur M., Bendell J., (2015) A phase II trial of mFOLFOX-bevacizumab (bev) followed by single-agent axitinib (ax) as maintenance therapy for patients (pts) with first-line metastatic colorectal cancer (mCRC). J Clin Oncol 33: Abstract e14673.
69. Jurgensmeier J., Schmoll H., Robertson J., Brooks L., Taboada M., Morgan S., et al. (2013) Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer 108: 1316-1323.
70. Kasi P., Hubbard J., Grothey A., (2015) Selection of biologics for patients with metastatic colorectal cancer: the role of predictive markers. Expert Rev Gastroenterol Hepatol 9: 273-276.
71. Khan K., Cunningham D., Chau I., Targeting angiogenic pathways in colorectal cancer: complexities, challenges and future directions. Curr Drug Targets. 2015 [Epub ahead of print]
72. Khoja L., Kumaran G., Zee Y., Murukesh N., Swindell R., Saunders M., et al. (2014) Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. J Clin Gastroenterol 48: 430-434.
73. Koutras A., Antonacopoulou A., Eleftheraki A., Dimitrakopoulos F., Koumarianou A., Varthalitis I., et al. (2012) Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J 12: 468-475.
74. Kubicka S., Greil R., Andre T., Bennouna J., Sastre J., Van Cutsem E., et al. (2013) Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol 24: 2342-2349.
75. Lee C., Lee M., Lee W., Kim J., Park K., Kim T., et al. (2015) Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. Am J Cancer Res 5: 72-86.
76. Lee J., Chow N., Wang S., Huang S., (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36: 748-753.
77. Lee S., Lopes de Menezes D., Vora J., Harris A., Ye H., Nordahl L., et al. (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11: 3633-3641.
78. Li J., Qin S., Xu R., Yau T., Ma B., Pan H., et al. (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase III trial. Lancet Oncol 16: 619-629.
79. Li J., Sainson R., Shi W., Leek R., Harrington L., Preusser M., et al. (2007) Delta-like 4 notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth. in vivo. Cancer Res 67: 11244-11253.
80. Li S., Padhani A., (2012) Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 35: 745-763.
81. Lim Y., Han S., Yoon J., Lee J., Lee J., Paeng J., et al. (2015) Clinical implication of anti-angiogenic effect of regorafenib in metastatic colorectal cancer. PLoS One 10: e0145004.
82. Liu Y., Starr M., Bulusu A., Pang H., Wong N., Honeycutt W., et al. (2013) Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med 2: 234-242.
83. LoRusso P., Krishnamurthi S., Youssoufian H., Hall N., Fox F., Dontabhaktuni A., et al. (2014) Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a phase I study. Invest New Drugs 32: 303-311.
84. Lv C., Wu S., Zheng D., Wu Y., Yao D., Yu X., (2013) The efficacy of additional bevacizumab to cytotoxic chemotherapy regimens for the treatment of colorectal cancer: an updated meta-analysis for randomized trials. Cancer Biother Radiopharm 28: 501-509.
85. Maeda K., Nishiguchi Y., Yashiro M., Yamada S., Onoda N., Sawada T., et al. (2000) Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 5: 373-378.
86. Maisonobe J., Garcia C., Necib H., Vanderlinden B., Hendlisz A., Flamen P., et al. (2013) Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy. Eur J Nucl Med Mol Imaging 40: 166-174.
87. Martinetti A., Miceli R., Sottotetti E., Di Bartolomeo M., de Braud F., Gevorgyan A., et al. (2014) Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers (Basel) 6: 1753-1768.
88. Masi G., Salvatore L., Boni L., Loupakis F., Cremolini C., Fornaro L., et al. (2015) Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol 26: 724-730.
89. Morgan B., Thomas A., Drevs J., Hennig J., Buchert M., Jivan A., et al. (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21: 3955-3964.
90. Mross K., Buchert M., Frost A., Medinger M., Stopfer P., Studeny M., et al. (2014) Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis. BMC Cancer 14: 510.
91. Nagengast W., Lub-de Hooge M., Oosting S., den Dunnen W., Warnders F., Brouwers A., et al. (2011) VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 71: 143-153.
92. Nakamura K., Taguchi E., Miura T., Yamamoto A., Takahashi K., Bichat F., et al. (2006) KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 66: 9134-9142.
93. Nakayama Y., Sako T., Shibao K., Okazaki K., Rempo N., Onitsuka K., et al. (2002) Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res 22: 2437-2442.
94. National Comprehensive Cancer Network. (2015) NCCN Clinical Practice Guidelines in Oncology™. Colon Cancer. Version 3. Available at: http://www.nccn.org/professionals/physician-gls/PDF/colon.pdf (. accessed 25 June 2015).
95. O'Neil B., Cainap C., Van Cutsem E., Gorbunova V., Karapetis C., Berlin J., et al. (2014) Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer. Clin Colorectal Cancer 13: 156-163.
96. Padhani A., Liu G., Koh D., Chenevert T., Thoeny H., Takahara T., et al. (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11: 102-125.
97. Pan Q., Chanthery Y., Liang W., Stawicki S., Mak J., Rathore N., et al. (2007) Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11: 53-67.
98. Passardi A., Nanni O., Tassinari D., Turci D., Cavanna L., Fontana A., et al. (2015) Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol 26: 1201-1207.
99. Pentheroudakis G., Kotoula V., Fountzilas E., Kouvatseas G., Basdanis G., Xanthakis I., et al. (2014) A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG). BMC Cancer 14: 111.
100. Pericay C., Folprecht G., Saunders M., Thomas A., Roh J., Lopez R., et al. (2012) Phase II randomized, noncomparative, open-label study of aflibercept and modified FOLFOX6 in the first-line treatment of metastatic colorectal cancer (AFFIRM). Ann Oncol 23: iv16.
101. Petrelli F., Borgonovo K., Cabiddu M., Ghilardi M., Lonati V., Maspero F., et al. (2013) FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer 12: 145-151.
102. ® (sunitinib malate) capsules, oral (package insert).
103. ® (axitinib) tablets for oral administration (package insert).
104. Price T., Hardingham J., Lee C., Weickhardt A., Townsend A., Wrin J., et al. (2011) Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 29: 2675-2682.
105. Roskoski R. Jr., (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356: 323-328.
106. Saltz L., Clarke S., Diaz-Rubio E., Scheithauer W., Figer A., Wong R., et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019.
107. Saltz L., Cox J., Blanke C., Rosen L., Fehrenbacher L., Moore M., et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914.
108. Samalin E., Bouche O., Thezenas S., Francois E., Adenis A., Bennouna J., et al. (2014) Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre phase I/II trial. Br J Cancer 110: 1148-1154.
109. Samalin E., De La, Fouchardiere C., Thezenas S., Boige V., Senellart H., Guimbaud R., et al. (2016) Sorafenib and irinotecan combination for pre-treated RAS-mutated metastatic colorectal cancer patients: a multicentre randomized phase II trial (NEXIRI 2). J Clin Oncol 34: Abstract 635.
110. ® (ziv-aflibercept) injection for intravenous infusion (package insert).
111. Schmoll H., Cunningham D., Sobrero A., Karapetis C., Rougier P., Koski S., et al. (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30: 3588-3595.
112. Semrad T., Kim E., Tanaka M., Sands J., Roberts C., Astrow S., et al. (2016) Phase II study of dovitinib in patients (Pts) progressing on anti-vascular endothelial growth factor (VEGF) therapy. J Clin Oncol 34: Abstract 616.
113. Shi Q., de Gramont A., Grothey A., Zalcberg J., Chibaudel B., Schmoll H., et al. (2015) Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J Clin Oncol 33: 22-28.
114. Simkens L., van Tinteren H., May A., Ten Tije A., Creemers G., Loosveld O., et al. (2015) Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase III randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385: 1843-1852.
115. Siu L., Shapiro J., Jonker D., Karapetis C., Zalcberg J., Simes J., et al. (2013) Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO. 20 Trial. J Clin Oncol 31: 2477-2484.
116. Stein A., Schwenke C., Folprecht G., Arnold D., (2016) Effect of application and intensity of bevacizumab-based maintenance after induction chemotherapy with bevacizumab for metastatic colorectal cancer: a meta-analysis. Clin Colorectal Cancer 15: e29-e39.
117. Tabernero J., Garcia-Carbonero R., Cassidy J., Sobrero A., Van C., Kohne C., et al. (2013) Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res 19: 2541-2550.
118. Tabernero J., Lenz H., Siena S., Sobrero A., Falcone A., Ychou M., et al. (2015a) Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 16: 937-948.
119. Tabernero J., Yoshino T., Cohn A., Obermannova R., Bodoky G., Garcia-Carbonero R., et al. (2015b) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase III study. Lancet Oncol 16: 499-508.
120. Tang P., Bentzen S., Chen E., Siu L., (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25: 4562-4568.
121. Tebbutt N., Wilson K., Gebski V., Cummins M., Zannino D., van Hazel G., et al. (2010) Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 28: 3191-3198.
122. Tournigand C., Andre T., Achille E., Lledo G., Flesh M., Mery-Mignard D., et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237.
123. Tuncbilek N., Karakas H., Altaner S., (2004) Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas. Abdom Imaging 29: 166-172.
124. Van Cutsem E., Bajetta E., Valle J., Kohne C., Hecht J., Moore M., et al. (2011a) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29: 2004-2010.
125. Van Cutsem E., Cervantes A., Nordlinger B., Arnold D,. (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25: iii1-iii9.
126. Van Cutsem E., Kohne C., Lang I., Folprecht G., Nowacki M., Cascinu S., et al. (2011b) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019.
127. Van Cutsem E., Prenen H., D'Haens G., Bennouna J., Carrato A., Ducreux M., et al. (2015) A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. Ann Oncol 26: 2085-2091.
128. Van Cutsem E., Rivera F., Berry S., Kretzschmar A., Michael M., DiBartolomeo M., et al. (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20: 1842-1847.
129. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausova J., Macarulla T., et al. (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499-3506.
130. Van der Veldt A., Lubberink M., Bahce I., Walraven M., de Boer M., Greuter H., et al. (2012) Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21: 82-91.
131. Wedge S., Kendrew J., Hennequin L., Valentine P., Barry S., Brave S., et al. (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389-4400.
132. Wilhelm S., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
133. Wilhelm S., Dumas J., Adnane L., Lynch M., Carter C., Schutz G., et al. (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129: 245-255.
134. Wilson M., Karakasis K., Oza A., (2015) Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncol 16: e32-e42.
135. Wolpin B., Ng K., Zhu A., Abrams T., Enzinger P., McCleary N., et al. (2013) Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist 18: 377-378.
136. Wood J., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., et al. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189.
137. Young P., Womeldorph C., Johnson E., Maykel J., Brucher B., Stojadinovic A., et al. (2014) Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. J Cancer 5: 262-271.